Figure 1.

Schematic view of the CRK and CRK domains in signaling pathways. (A) Multiple oncogenic pathways in NSCLC and other malignancies that involve CRK are demonstrated. Additionally, a number of downstream effectors of CRK are shown. (B) Protein domains of v-crk, CRK-I, and CRK-II including Src Homology domains SH2, SH3N, and SH3C are shown. **Percentage of sequence similarity between CRK-II and CRK-L domains. (C) Schematic view of CRK SH2 and SH3 domains during effective signal transduction. Additionally, the strategy shown is of using CRK-I domain overexpression to saturate the upstream stimuli and downstream CRK effectors, thereby blocking the CRK signaling.